Whereas most patients maintained humoral immunity throughout the observation period, we observed reduced cellular immune reactivity as measured by the ancestral-strain-stimulated ELISpot assay in a subset of patients. Half of the individuals (50%; 14/28) maintained cellular immunity three months after the fifth dose, despite acquiring humoral immunity.
19,148 Deaths · 90,674 Hospitalizations · 119,743 Urgent Care · 201,087 Doctor Office Visits · 2,544 Anaphylaxis · 6,394 Bell's Palsy · 2,068 Miscarriages · 9,505 Heart Attacks · 28,769 Myocarditis · 18,613 Permanently Disabled · 9,326 Thrombocytopenia · 15,395 Life Threatening · 36,911 Severe Allergic Reaction · 8,251 Shingles · 5,319 Myocarditis/Pericarditis · 3,727 Thrombocytopenia/Low Platelet ·
·
19,148 Deaths · 90,674 Hospitalizations · 119,743 Urgent Care · 201,087 Doctor Office Visits · 2,544 Anaphylaxis · 6,394 Bell's Palsy · 2,068 Miscarriages · 9,505 Heart Attacks · 28,769 Myocarditis · 18,613 Permanently Disabled · 9,326 Thrombocytopenia · 15,395 Life Threatening · 36,911 Severe Allergic Reaction · 8,251 Shingles · 5,319 Myocarditis/Pericarditis · 3,727 Thrombocytopenia/Low Platelet ·
·